STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Becton Dickinson insider files Form 144 to sell 863 shares via Merrill Lynch

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filed for Becton, Dickinson and Co. (BDX) indicates a proposed sale of 863 common shares, with an aggregate market value of $165,879.90, to be sold approximately on 08/08/2025 on the NYSE through Merrill Lynch. The filing shows 286,627,469 shares outstanding, so the proposed sale is a very small fraction of the company’s total shares. The securities were acquired on 01/24/2024 as a stock bonus from Claire Marie Fraser and were paid as compensation. The filer represents there are no undisclosed material adverse facts.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small, routine insider notice; negligible market impact.

The filing documents a proposed sale of 863 common shares (aggregate value $165,879.90) to be executed via Merrill Lynch on the NYSE. Relative to 286,627,469 shares outstanding, this sale is immaterial (~0.0003% of outstanding shares), so it is unlikely to affect market liquidity or valuation. The shares were acquired as a stock bonus on 01/24/2024 and paid as compensation, and no other recent sales are reported.

TL;DR: Proper disclosure under Rule 144; no governance red flags apparent.

The notice fulfills Rule 144 disclosure elements: broker, approximate sale date, quantity, acquisition date, and nature of acquisition (stock bonus from Claire Marie Fraser). The filer affirms absence of undisclosed material adverse information. With no reported sales in the past three months and a de minimis sale size, this filing appears routine from a governance and compliance perspective.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the BDX Form 144 report?

The filing reports a proposed sale of 863 common shares of Becton, Dickinson and Co. with an aggregate market value of $165,879.90.

When were the shares acquired and how?

The shares were acquired on 01/24/2024 as a stock bonus from Claire Marie Fraser and paid as compensation.

When is the approximate sale date and where will the sale occur?

The approximate date of sale is listed as 08/08/2025, and the filing specifies the NYSE with Merrill Lynch as the broker.

How material is this sale relative to outstanding shares of BDX?

The filing lists 286,627,469 shares outstanding; the proposed 863-share sale is roughly 0.0003% of that total, which is immaterial.

Are there any other sales by this person in the past three months?

The filing reports Nothing to Report for securities sold during the past three months.
Becton Dickinson & Co

NYSE:BDX

BDX Rankings

BDX Latest News

BDX Latest SEC Filings

BDX Stock Data

57.21B
283.69M
0.57%
92.26%
1.59%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
FRANKLIN LAKES